Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus LIBRITABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus LIBRITABS.
CENTRAX vs LIBRITABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Libritabs (chlordiazepoxide) is a benzodiazepine that binds to GABA-A receptors at the gamma subunit, potentiating GABAergic inhibition and producing anxiolytic, sedative, and anticonvulsant effects.
10-30 mg orally, 3-4 times daily.
5-10 mg orally 3-4 times daily; up to 30 mg/day in divided doses for severe anxiety.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Terminal elimination half-life is 15-20 hours; clinical context: steady-state reached in 3-5 days with daily dosing, prolonged in hepatic impairment.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Renal: 70-80% as unchanged drug and glucuronide conjugate; fecal: 15-20% via biliary elimination.
Category C
Category C
Benzodiazepine
Benzodiazepine